How is Sublocade (buprenorphine) administered, what are its contraindications and monitoring requirements, and what alternatives exist for treating opioid use disorder in adults?

Sublocade (Buprenorphine Extended-Release) for Opioid Use Disorder

Administration

Sublocade is administered exclusively by healthcare providers as a monthly subcutaneous injection into the abdomen, thigh, buttock, or back of the upper arm, with a recommended dosing schedule of two initial 300 mg injections followed by 100 mg monthly maintenance doses. 1

Key Administration Details:

• Route and sites: Subcutaneous injection only—never intravenous, as this can cause serious harm or death 1

• Approved injection locations: Abdomen (original FDA-approved site), upper arm, thigh, or buttocks 2

• Dosing schedule:

  • Two initial doses of 300 mg
  • Followed by 100 mg monthly maintenance doses
  • The second injection may be given as early as one week after the first injection 1
  • Maintenance dose may be increased to 300 mg monthly if benefits outweigh risks 1
  • Minimum 26 days between subsequent doses 3

• Injection site management: Rotate sites between doses; do not rub or massage the injection site; the depot may be visible or palpable as a small bump that decreases over time 1

Pre-Administration Requirements:

Patients not currently on buprenorphine must receive an initial test dose (e.g., 4 mg) of transmucosal buprenorphine before the first Sublocade injection to verify tolerability. 1 This critical step prevents precipitated withdrawal, particularly important given the high prevalence of fentanyl use 4.

• Monitor patients in the healthcare setting after injection for symptoms of worsening withdrawal or sedation 1
• Patients' symptoms should be stable or improving before discharge 1
• Patients already stabilized on sublingual buprenorphine can transition directly to Sublocade 1

Contraindications

The only absolute contraindication to Sublocade is hypersensitivity to buprenorphine or any ingredients in the prefilled syringe (ATRIGEL® delivery system). 1

Situations Requiring Extreme Caution or Avoidance:

• Moderate to severe hepatic impairment: Not recommended 1
• Respiratory compromise: Including lung problems, curves in spine affecting breathing 1
• Concurrent CNS depressants: Concomitant use with benzodiazepines, gabapentinoids, alcohol, or other opioids significantly increases risk of respiratory depression, coma, and death 1

Monitoring Requirements

Initial Monitoring:

• Post-injection observation: Monitor for withdrawal symptoms and sedation in healthcare setting before discharge 1
• Injection site examination: Assess for signs of infection, tampering, or attempts to remove the depot at each visit 1

Ongoing Monitoring:

• Liver function tests: Monitor before and during treatment 1
• Respiratory status: Particularly in patients with risk factors for respiratory depression 1
• Adrenal function: If adrenal insufficiency suspected 1
• Withdrawal symptoms: Monitor for several months after discontinuation, as detectable buprenorphine levels persist for extended periods 1

Safety Considerations:

• Naloxone co-prescription: Strongly consider prescribing naloxone or nalmefene at initiation or renewal, as patients with OUD remain at risk for relapse and overdose 1, 5
• Injection site reactions: Occurred in >5% of patients but were mostly mild and not treatment-limiting 3
• Common adverse events (≥5%): Constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, injection site pain 1

Alternatives for Opioid Use Disorder Treatment

First-Line Medication Options:

Methadone and sublingual buprenorphine are the primary alternatives to Sublocade, both demonstrating reduced overdose and all-cause mortality. 5

1. Sublingual buprenorphine/naloxone:

   • Office-based treatment with take-home dosing 5
   • Requires daily adherence but offers flexibility 6
   • Risk of diversion and misuse 6
   • Recent evidence shows comparable 7-day and 30-day treatment engagement to extended-release formulations (38.5% vs 40.5% at 7 days) 4

2. Methadone:

   • Full opioid agonist with proven mortality reduction 5
   • Only available through federally regulated clinics in the US, requiring in-person visits 5
   • Less tight μ-receptor binding than buprenorphine, allowing better response to additional opioid analgesics for acute pain 7

3. Naltrexone (extended-release injectable):

   • Opioid antagonist requiring complete opioid detoxification before initiation 5
   • Does not reduce mortality as effectively as opioid agonist therapies 5
   • May be preferred by patients who want non-opioid treatment 6

Other Long-Acting Buprenorphine Formulations:

• CAM 2038 (Buvidal): Weekly and monthly subcutaneous depot formulations 8
• Probuphine: Six-month buprenorphine implant 8

Treatment Selection Algorithm:

Choose methadone or buprenorphine over naltrexone based on superior mortality reduction. 5 Within buprenorphine formulations:

• Select Sublocade or other long-acting formulations when:

  • Diversion risk is high
  • Adherence to daily medication is challenging
  • Patient prefers monthly dosing
  • Healthcare-supervised administration is feasible 3, 6

• Select sublingual buprenorphine when:

  • Patient prefers daily self-administration
  • Access to monthly injection visits is limited
  • Rapid dose adjustments may be needed 6

Critical Pitfall—Acute Pain Management:

When patients on Sublocade require treatment for acute pain, buprenorphine's high μ-receptor affinity complicates opioid analgesia. 7 Four evidence-based approaches exist:

1. Continue Sublocade and titrate short-acting opioid analgesics to higher doses to compete at the μ-receptor (monitor closely for respiratory depression if Sublocade is discontinued) 7
2. Divide daily buprenorphine dose to every 6-8 hours for analgesic effect, plus additional opioid agonists as needed 7
3. Discontinue buprenorphine and use full opioid agonists, then reinitiate with induction protocol after pain resolves 7
4. Convert to methadone 30-40 mg/day (which binds less tightly to μ-receptors), add opioid analgesics as needed, then reinitiate buprenorphine after pain resolves 7

In all cases, naloxone must be available and respiratory status frequently monitored due to variable buprenorphine dissociation rates. 7

REMS Program Requirement:

Sublocade is only available through the restricted SUBLOCADE REMS Program—healthcare settings and pharmacies must be certified to order and dispense it. 1 This restriction exists due to the serious risk of harm or death from intravenous administration 1.

Long-Term Efficacy Data:

After 12 months of treatment, 61.5-75.8% of patients maintained abstinence, with 50.5-50.6% retention rates 9. Treatment-emergent adverse events, including injection-site reactions, decreased in the second 6 months compared to the first 6 months of treatment 9. Patients on extended-release formulations reported lower craving scores and fewer days of illicit opioid use compared to sublingual buprenorphine 4.